1	Impaired cellular immunity to SARS-CoV-2 in severe COVID-19							
2	patients							
3								
4	Ling Ni <sup>1, 2, *</sup> , Meng-Li Cheng <sup>3,4 *</sup> , Hui Zhao <sup>4, *</sup> , Yu Feng <sup>1</sup> , Jingyuan Liu <sup>5</sup> , Fang Ye <sup>6</sup> ,							
5	Qing Ye <sup>4</sup> , Gengzhen Zhu <sup>1</sup> , Xiaoli Li <sup>1</sup> , Pengzhi Wang <sup>1</sup> , Jing Shao <sup>1</sup> , Yong-Qiang							
6	Deng <sup>4</sup> , Peng Wei <sup>1</sup> , Fang Chen <sup>7</sup> , Cheng-Feng Qin <sup>4,</sup> , Guoqing Wang <sup>3</sup> , Fan Li <sup>3, 8, #</sup> ,							
7	Hui Zeng <sup>5, #</sup> , Chen Dong <sup>1, 2, 9, 10, #</sup>							
8								
9	1. Institute for Immunology and School of Medicine, Tsinghua University, Beijing							
10	100084, China							
11	2. Center for Human Disease Immuno-monitoring, Beijing Friendship Hospital,							
12	Beijing 100050, China							
13	3. College of Basic Medical Science, Jilin University, Changchun 130021, China							
14	4. Department of Virology, State Key Laboratory of Pathogen and Biosecurity,							
15	Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences,							
16	Beijing 100071, China							
17	5. Beijing Ditan Hospital, Capital Medical University, and Beijing Key Laboratory							
18	of Emerging Infectious Diseases, Beijing100015, China							
19	6. Department of Hematology, Chui Yang Liu Hospital affiliated to Tsinghua							
20	University, Beijing 100022, China							
21	7. Department of Cardiology, Chui Yang Liu Hospital affiliated to Tsinghua							
22	University, Beijing100022, China							
23	8. China-Japan Union Hospital, Jilin University, Changchun 130033, China							
24	9. Beijing Key Lab for Immunological Research on Chronic Diseases, Beijing							
25	100084, China							

### 1 10. Lead Contact

2 \*These authors contributed equally to this work.

- 4 #To whom correspondence should be addressed: Chen Dong,
- 5 chendong@tsinghua.edu.cn; or zenghui@ccmu.edu.cn; Fan Li, lifan@jlu.edu.cn

#### 1 SUMMARY

2

3 The World Health Organization has declared SARS-CoV-2 virus outbreak a 4 world-wide pandemic. Individuals infected by the virus exhibited different degrees of 5 symptoms, the basis of which remains largely unclear. Currently, though 6 convalescent individuals have been shown with both cellular and humoral immune 7 responses, there is very limited understanding on the immune responses, especially 8 adaptive immune responses, in patients with severe COVID-19. Here, we examined 9 10 blood samples from COVID-19 patients with acute respiratory distress syndrome 10 (ARDS). The majority of them (70%) mounted SARS-CoV-2-specific humoral 11 immunity with production of neutralizing antibodies. However, compared to healthy 12 controls, the percentages and absolute numbers of both NK cells and CD8<sup>+</sup> T cells 13 were significantly reduced, accompanied with decreased IFN<sub>Y</sub> expression in CD4<sup>+</sup> T 14 cells in peripheral blood from severe patients. Most notably, we failed in detecting 15 SARS-CoV-2-specific IFNy production by peripheral blood lymphocytes from these 16 patients. Our work thus indicates that COVID-19 patients with severe symptoms are 17 associated with defective cellular immunity, which not only provides insights on 18 understanding the pathogenesis of COVID-19, but also has implications in 19 developing an effective vaccine to SARS-CoV-2.

- 20
- 21

22 Keywords: SARS-CoV-2, acute respiratory distress syndrome, adaptive immunity, 23 neutralization antibody, T cells

- 24
- 25
- 26

#### 1 Introduction

2 Identified in December, 2019, coronavirus disease 2019 (COVID-19) caused by 3 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Wang et al., 2020a) 4 has become a global public health threat. As of July 17th, 2020, 13,378,853 global 5 cases were confirmed, of which 580,045 patients died (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-6

reports). The high infection rate and rapid spread make it a world-wide emergency
(Di Pierro et al., 2020). However, up to date, there is no specific anti-viral medicine
or vaccine available to prevent or treat COVID-19 and the current standard care
relies on supportive treatments.

11 Approximately 80% of COVID-19 cases are asymptomatic or manifest mild 12 symptoms resembling simple upper respiration tract infection. The remaining 13 COVID-19 patients show severe or critical symptoms with severe pneumonia and 14 acute respiratory distress syndrome (ARDS) (Gruszecka and Filip, 2020). How the 15 immune system modifies and controls the infection is still not well understood, which 16 may underscore the different degrees of symptoms amongst the population. Several 17 papers were reported on the adaptive immune responses in the recovered mild 18 COVID-19 patients. We detected SARS-CoV-2-specific antibodies and T cells in 19 convalescent individuals (Ni et al., 2020). Grofoni et al also found that ~70% and 100% 20 of COVID-19 convalescent subjects with mild and severe symptoms developed SARS-CoV-2-specific CD8<sup>+</sup> and CD4<sup>+</sup> T cells, respectively (Grifoni et al., 2020). 21 22 However, there is very limited understanding on immune responses in severe 23 COVID-19 patients during hospitalization. In a retrospective study, Chen et al 24 observed that absolute numbers of T lymphocytes, both CD4<sup>+</sup> and CD8<sup>+</sup>, were 25 markedly lower in severe patients than those in moderate cases (Chen et al., 2020).

1 In contrast to the aforementioned study, Zheng et al did not observe reduced 2 lymphocytes in the severe disease group, but T cells showed elevated exhaustion 3 levels and reduced functional heterogeneity (Zheng et al., 2020). Using megapools 4 of overlapping or prediction-based peptides covering the SARS-CoV-2 proteome, Weiskopf et al found CD4<sup>+</sup> and CD8<sup>+</sup> T cells showed activation marker expression in 5 6 10 out of 10 and 8 out of 10 patients with severe COVID-19 during hospitalization. 7 respectively (Weiskopf et al., 2020). For humoral responses, Lynch et al found that 8 antibody responses were higher in patients with severe than mild disease (Lynch et 9 al., 2020). And high levels of neutralizing antibodies was induced 10 days post onset 10 in both mild and severe patient, which were higher in severe group (Wang et al., 11 2020b).

In order to understand immune responses and the mechanism underlying the pathogenesis of severe COVID-19, we collected blood samples from 10 patients with ARDS, analyzed their cellular and humoral responses specific to SARS-CoV-2, and compared severe and convalescent patients. Our data reveal defective cellular immunity associated with severe COVID-19. This study provides new insights on the precise treatment of COVID-19 patients and evaluation of candidate vaccines.

18

#### 1 Results

#### 2 Detection of SARS-CoV-2-specific antibodies in severe COVID-19 subjects

3 To understand the immune responses to SARS-CoV-2 in severe patients, we 4 studied 10 patients with acute respiratory distress syndrome (ARDS). Their clinical 5 and pathological characteristics are shown in Table 1. All the patients were 6 hospitalized at Beijing Ditan Hospital and showed severe symptoms via CT scan and 7 were positive in SARS-CoV-2 nucleic acid testing. The mean age was 57.5 years 8 and half of them were female. Among them, 8 (80%) showed lymphopenia. As of 9 today, 1 patient (Pt#9) passed away and the remaining ones had recovered and 10 were discharged from hospital. The blood samples were obtained within 20 days 11 post symptom onset and the detail sampling day for each patient was also shown in 12 Table 1. Human AB serum collected from healthy male AB donors in the US 13 (GemCell, CA) was used as a negative control. Additionally, sera from nine healthy 14 donors were obtained before the SARS-CoV-2 outbreak (HD#1-9). 5 additional 15 healthy donors (HD#10-14) without SARS-CoV-2 infection were analyzed in our T 16 cell assays.

17 Using sera from patients and healthy donors, IgG and IgM specific to SARS-18 CoV-2 NP and S-RBD antigens were analyzed using ELISA assay previously 19 reported (Ni et al., 2020). The individual serum samples were performed by serial 20 dilutions to calculate the area under the curve (AUC) values (Figure 1A). Compared 21 with healthy donors, patients with severe COVID-19 showed significantly elevated 22 anti-NP IgG AUC values (Figure 1B). The AUC values of anti-S-RBD IgG in severe 23 cases were also significantly increased compared to those in healthy controls. 24 Serum NP- and S-RBD-specific IgM antibodies showed significantly higher AUC 25 values in severe COVID-19 patients than in healthy controls (Figure 1B). Notably,

patients #1, 4 and 7 did not develop NP- and S-RBD -specific antibody responses,
including IgM and IgG. As shown in Figure 1C, anti-NP and S-RBD IgG in severe
patients was mainly IgG1 isotype, as in convalescent individuals (Ni et al., 2020). We
did not detect IgG2 to either NP or S-RBD proteins (data not shown).

In order to understand the pathogenic mechanisms in severe patients, we compared the levels of virus-specific IgG or IgM in these patients with those in convalescent individuals. Serum from one convalescent COVID-19 patient was used as a positive control standard to calculate the antibody titers (relative units) for all samples using non-linear regression interpolations (Grifoni et al., 2020). Of note, we observed no significant differences in anti-NP/S-RBD IgG or IgM between these two groups (Figure 1D).

Taken together, these findings indicate that most severe COVID-19 patients mounted IgG and IgM responses specific to SARS-CoV-2 proteins, NP and S-RBD. However, the levels of humoral immune responses varied among the patients.

15

#### 16 Measurement of neutralizing antibody production in severe COVID-19 subjects

17 To determine the neutralization capacity in sera from patients with severe 18 COVID-19, we performed pseudovirus particle-based neutralization assay as 19 previously described (Ni et al., 2020). As shown in Figure 2A and 2B, patients #1, 4 20 and 7, did not produce neutralizing antibodies, while patient #3 had a high 21 neutralizing antibody titer (NAT50>1000). Most severe patients (70%) had protective 22 humoral immunity to SARS-CoV-2. Notably, sera from severe patients did not show 23 significantly reduced NAT50 values than convalescent sera (Figure 2C). About 30% 24 of severe patients and 8% of convalescent individuals did not produce neutralizing 25 antibodies, respectively (Figure 2D). Around 40%, 20% and 10% of severe patients

1 showed low (NAT50: 30-500), medium (NAT50: 500-1000) and high (NAT50: >1000)

2 NAT50, respectively, while 50%, 21% and 21% in the convalescent group did.

Nonetheless, our results indicate that most severe patients had serum
neutralizing antibodies to SARS-CoV-2 infection.

5

#### 6 Lymphocyte numbers and function in severe COVID-19 subjects

7 To analyze cellular immune responses to SARS-CoV-2, peripheral blood 8 mononuclear cells (PBMCs) from 10 patients with severe COVID-19 and 5 healthy 9 donors were phenotypically analyzed by flow cytometry (Figure 3A). We did not 10 detect live PBMCs in 3 out of 10 patients (Pts# 3, 4 and 5), possibly due to technical 11 issues during cryopreservation. Compared to healthy donors, there was a significant 12 decrease in the percentages of NK cells in the severe patients, but similar 13 frequencies of NKT cells (Figure 3B). Although there was a trend towards increased 14 frequencies of T cells (CD3<sup>+</sup>CD56<sup>-</sup>) in the patient blood, the absolute numbers of T 15 cells were significantly decreased compared to those in blood from healthy controls 16 (Figure 3C). Notably, the percentages and absolute numbers of CD8<sup>+</sup> T cells were 17 reduced dramatically, while the frequency of CD4<sup>+</sup> T cells was elevated compared 18 with those in healthy donors. As a result, the CD4:CD8 ratios were significantly 19 higher in severe patients than in the healthy donors (6.7  $\pm$  1.3 in COVID-19 vs 2.5  $\pm$ 20 0.3 in HD, P=0.0226) (Figure 3B). Thus, the severe patients exhibited reduced 21 cytotoxic lymphocytes, both NK and CD8<sup>+</sup> T cells.

To further assess the function of the T cells in the severe patients, we stimulated T cells with phorbol myristate acetate (PMA) and ionomycin and then measured cytokine production. As shown in Figure 4A and 4B, CD4<sup>+</sup> T cells from severe patients expressed significantly lower levels of IFNγ than those from healthy donors.

We observed no apparent difference in the frequencies of  $TNF\alpha$ -expressing CD4<sup>+</sup> T cells, but significantly reduced percentages of  $IFN\gamma^+$   $TNF\alpha^+$  T cells (Figure 4C and 4D), consistent with a published report (Chen et al., 2020). Only 2 out of 7 patients had detectable IL-17A<sup>+</sup> CD4<sup>+</sup> T cells, which expressed  $TNF\alpha$ , but not IFN $\gamma$  (Figure 4D).

Despite the decreased frequencies of  $CD8^+ T$  cells in PBMCs from the patients, these  $CD8^+ T$  cells expressed similar levels of cytokines IFN $\gamma$  and TNF $\alpha$  as the ones from healthy donors (Figure 4E and 4F). In addition, similar frequencies of IFN $\gamma^+TNF\alpha^+ CD8^+ T$  cells were found in severe patients and healthy donors (Figure 4G).

We also evaluated capacities of cytokine production in CD3<sup>-</sup> cells, likely NK cells. As shown in Figure 4H, these cells in severe patients expressed significantly reduced levels of IFN $\gamma$  and TNF $\alpha$  than those in healthy donors. We did not observe significant difference in terms of the frequency of IFN $\gamma^+$  TNF $\alpha^+$  cells between these two groups (Figure 4H).

16

#### 17 Cellular immune responses to SARS-CoV-2 in severe COVID-19 subjects

To further measure virus-specific cellular immunity, we treated PBMCs with recombinant NP, S-RBD and S proteins, followed by IFNγ ELISpot analysis. As shown in Figure 5A, the absolute numbers of T cells produced IFNγ in response to anti-CD3 were decreased dramatically in PBMCs from severe patients than those from healthy donors. More strikingly, we did not detect any SARS-CoV-2-specific T cells in all the tested severe patients, whereas one out of ten T cells could secret IFNγ after exposure to NP protein in convalescent individuals (Figure 5B).

- 1 Thus, T cells in the severe COVID-19 patients failed in developing cellular
- 2 immunity to SARS-CoV-2.
- 3
- 4

#### 1 Discussion

In this study, we characterized humoral and cellular immunity in severe COVIDpatients during hospitalization. Although most patients developed anti-SARS-CoV-2 IgG and IgM responses, humoral immune responses varied widely among the patients. The percentages and absolute numbers of both NK cells and CD8<sup>+</sup> T cells were significantly reduced, accompanied with decreased Th1 cell response in peripheral blood from severe patients. Most notably, we failed in SARS-CoV-2specific IFNy production in these patients.

9 In this study, most severe patients had reduced Th1 cell responses, consistent 10 with the published report (Chen et al., 2020). Another report showed that peripheral 11 blood of a severe COVID-19 patient had a strikingly high number of CCR6<sup>+</sup> Th17 12 cells (Xu et al., 2020). In addition, several papers proposed use of therapies directed 13 at Th17 cells and IL-17A signaling in treating COVID-19 patients (De Biasi et al., 14 2020; Orlov et al., 2020; Wu and Yang, 2020). However, we observed no significant 15 Th17 cell responses in most of the severe patients (5/7) with only one patient 16 showing elevated IL-17A expression. Several possibilities may account for the 17 discrepancy. One is different markers used for defining Th17 cells. The above-18 mentioned paper used CCR6 on CD4<sup>+</sup> T cells to define Th17 cells, whereas we used 19 IL-17A expression in CD4<sup>+</sup> T cells. Another is different patient cohort and disease 20 severity. Sample timing during disease course is another possibility, since T cell 21 responses are dynamic. Given not all the severe COVID-19 patients had increased 22 IL-17A expression, one may not want to treat all patients with IL-17A inhibitors.

5 healthy donors (HD#10-14) with a mean age of 29.4 years were included in our
T cell assays, which are not age-matched with severe patients with a mean age of
57 years. Compared to healthy controls, severe patients showed reduced

percentages of CD8<sup>+</sup> T cells and IFNγ-expressing CD4<sup>+</sup> T cells. Previously, Carr et al
 found that frequencies of Th1 and CD8<sup>+</sup> T cells were enhanced with age (Carr et al.,
 2016). Thus, the differences we observed between healthy controls and severe
 patients were unlikely caused by age.

In our study, antigens-specific IFNγ expression was not detected in severe patients, in contrast to the report (Weiskopf et al., 2020). We used antigen-mediated IFNγ ELISpot analysis to detect antigen-specific T cells, while the other group used T cell receptor-dependent activation marker assay in measuring the expression of CD137 and CD69. Since AIM assay did not measure effector function by T cells, it is possible that virus-specific T cells are "exhausted". Different patient cohort and sample timing may account for the different results.

In summary, we detected anti-SARS-CoV-2 antibody responses in most severe cases, while impaired cellular responses were observed in all severe COVID-19 patients. Our results thus provide insight in the pathogenesis of severe COVID-19. They suggest that induction of cellular immunity is vital in controlling SARS-CoV-2 infection, which also has implications in development of an effective vaccine.

17

#### 1 ACKNOWLEDGEMENT

2 We thank Weijin Huang and Jianhui Nie from the National Institutes for Food and 3 Drug Control for sharing the plasmids for pseudovirus package. This work was 4 supported in part by grants from the National Key Research and Development Program of China (2016YFC0906200 to CD, 2016YFC130390 to LN , and 5 6 2020YFA0707800 to XW), Natural Science Foundation of China (31991173, 7 31821003 and 31991170 to CD), Beijing Municipal Science and Technology 8 (Z181100001318007, Z181100006318015 and Z171100000417005 to C.D.), 9 Zhejiang University Foundation (2020XGZX014 to CD), Tsinghua University (to CD) and Science and Technology Development Plan Project of Jilin Province 10 11 (20200901007SF to F.L.).

12

#### 13 AUTHOR CONTRIBUTIONS

L.N. and C.D. designed the research and analyzed the data. Y.F. and F.C. collected clinical specimens with mild COVID-19; J.L. and H.Z. collected clinical specimens with severe COVID-19; Y.D., X.L. and Q.Y. did most of the experiments at a P3 laboratory. M.C., Y.F., H.Z., Q.Y., Z.G., L.X., P. W., S.J. and D.Y. performed some experiments or prepared key reagents; L.N. and C.D. analyzed the results; L.N. and C.D. wrote the manuscript.

20

#### 21 Conflict of interest

22 The authors declare that there are no conflicts of interest to disclose.

23

24

25

26

#### 1 Figure legends

2

# Figure 1. Presence of SARS-CoV-2 NP- and S-RBD-specific antibodies in severe COVID-19 patients.

5 (A) Titration of individual serum samples. (B) Data from the same experiments as (A) 6 were presented as area under curve (AUC). (C) IgG isotypes of 10 COVID-19 7 patients to recombinant NP and S-RBD. (D) Serum ELISA titers to NP and S-RBD in 8 sera from convalescent individuals (n=14) and severe patients (n=10). The 9 experiment was performed in duplicates. Date are presented as Mean ± SEM. NP, 10 nucleocapsid protein. S-RBD, receptor binding domain of spike protein. HD, healthy 11 donor. Pt, patient. AUC, area under curve. HD#1-9, the sera were collected before 12 SARS-CoV-2 outbreak. \*P<0.05, 0.05<\*\*P<0.001, \*\*\*P<0.001. ns, not significant.

13

## Figure 2. Measurement of neutralizing antibody titers in severe COVID-19 cases.

(A) Neutralizing curves of 10 COVID-19 patients measured by pseudovirus-based
assay. The experiment with patients was performed in duplicates. (B) Neutralizing
antibody titers of 10 severe COVID-19 patients. (C) Comparison of NAT50 between
convalescent subjects (n=14) and severe patients (n=10). Date are presented as
Mean ± SEM. (D) Pie plot showing NAT50 range in severe and convalescent
patients. HD, healthy donor (HD#10-14). Pt, patient. NAT50, neutralizing antibody
titers. \*P<0.05, 0.05<\*\*P<0.001, \*\*\*P<0.001. ns, not significant.</li>

23

Figure 3. Phenotypic analysis of blood lymphocytes in severe COVID-19
 patients.

(A) Phenotypic analysis of PBMCs from one representative COVID-19 patient. (B)
Summarized data on the frequencies of different immune cell subsets in COVID-19
patients and the ratio of CD4:CD8 T cells. (C) Summarized data on the absolute
numbers of different immune cell subsets in COVID-19 patients. HD, healthy donors
(HD#10-14); Pt, patients (n=7). Date are presented as Mean ± SEM. \*P<0.05,</li>
0.05<\*\*P<0.001, \*\*\*P<0.001. ns, not significant.</li>

7

#### 8 Figure 4. Cellular functionality of T cells in severe COVID-19 cases.

9 (A) Intracellular cytokine staining of CD3<sup>+</sup>CD56<sup>-</sup>CD8<sup>-</sup> T cells. (B) Summarized data 10 on the frequencies of cytokine-producing CD3<sup>+</sup>CD56<sup>-</sup>CD8<sup>-</sup> T cells as indicated. (C) 11 Representative FACS plots showing polyfunctional CD3<sup>+</sup>CD56<sup>-</sup>CD8<sup>-</sup> T cells. (D) 12 Summarized data on the frequencies of polyfunctional CD3<sup>+</sup>CD56<sup>-</sup>CD8<sup>-</sup> T cells as indicated. (E) Intracellular cytokine staining of CD3<sup>+</sup>CD56<sup>-</sup>CD8<sup>+</sup> T cells. (F) 13 14 Summarized data on the frequencies of cytokine-producing CD3<sup>+</sup>CD56<sup>-</sup>CD8<sup>+</sup> T cells 15 as indicated. (G) Summarized data on the frequencies of polyfunctional CD3<sup>+</sup>CD56<sup>-</sup> 16 CD8<sup>+</sup> T cells as indicated. (H) Summarized data on the frequencies of cytokine-17 producing CD3<sup>-</sup> cells as indicated. HD, healthy donors (HD#10-14); Pt, patients 18 (n=7). Date are presented as Mean ± SEM. \*P<0.05, 0.05<\*\*P<0.001, \*\*\*P<0.001. 19 ns, not significant.

20

# Figure 5. T cell responses to recombinant SARS-CoV-2 proteins in COVID-19 patients.

(A) IFNγ ELISpot analysis of COVID-19 patients to anti-CD3 antibody. HD, healthy
 donors (HD#10-14); Pt, patients (n=7). The experiment with patients was performed
 in duplicates. (B) The ratios of IFNγ-producing T cells in response to NP or anti-CD3

1	stimulation in both convalescent (n=14) and severe (n=7) patients. Date are
2	presented as Mean ± SEM. *P<0.05, 0.05<**P<0.001, ***P<0.001.
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	

### 1 Reference

- 2 Carr, E.J., Dooley, J., Garcia-Perez, J.E., Lagou, V., Lee, J.C., Wouters, C., Meyts, I., Goris, A.,
- 3 Boeckxstaens, G., Linterman, M.A., and Liston, A. (2016). The cellular composition of the
- 4 human immune system is shaped by age and cohabitation. Nat Immunol 17, 461-468.
- 5 Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H.,
- 6 et al. (2020). Clinical and immunological features of severe and moderate coronavirus
- 7 disease 2019. J Clin Invest *130*, 2620-2629.
- 8 De Biasi, S., Meschiari, M., Gibellini, L., Bellinazzi, C., Borella, R., Fidanza, L., Gozzi, L.,
- 9 Iannone, A., Lo Tartaro, D., Mattioli, M., et al. (2020). Marked T cell activation, senescence,
- exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat Commun
   11, 3434.
- 12 Di Pierro, F., Bertuccioli, A., and Cavecchia, I. (2020). Possible therapeutic role of a highly
- 13 standardized mixture of active compounds derived from cultured Lentinula edodes mycelia
- 14 (AHCC) in patients infected with 2019 novel coronavirus. Minerva Gastroenterol Dietol.
- 15 Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings,
- 16 S.A., Sutherland, A., Premkumar, L., Jadi, R.S., *et al.* (2020). Targets of T Cell Responses to
- 17 SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell.
- 18 Gruszecka, J., and Filip, R. (2020). Preliminary information on prevention of infections
- 19 caused by SARS-COV-2 virus in endoscopic laboratories. Ann Agric Environ Med 27, 171-174.
- 20 Lynch, K.L., Whitman, J.D., Lacanienta, N.P., Beckerdite, E.W., Kastner, S.A., Shy, B.R.,
- 21 Goldgof, G.M., Levine, A.G., Bapat, S.P., Stramer, S.L., et al. (2020). Magnitude and kinetics
- of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Clin Infect
   Dis.
- 24 Ni, L., Ye, F., Cheng, M.L., Feng, Y., Deng, Y.Q., Zhao, H., Wei, P., Ge, J., Gou, M., Li, X., et al.
- (2020). Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19
   Convalescent Individuals. Immunity *52*, 971-977 e973.
- 27 Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., *et al.*
- (2020). Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.
- 29 Emerg Microbes Infect *9*, 680-686.
- 30 Orlov, M., Wander, P.L., Morrell, E.D., Mikacenic, C., and Wurfel, M.M. (2020). A Case for
- 31 Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections. J Immunol.
- Wang, C., Horby, P.W., Hayden, F.G., and Gao, G.F. (2020a). A novel coronavirus outbreak of
- 33 global health concern. Lancet *395*, 470-473.
- Wang, Y., Zhang, L., Sang, L., Ye, F., Ruan, S., Zhong, B., Song, T., Alshukairi, A.N., Chen, R.,
- Zhang, Z., *et al.* (2020b). Kinetics of viral load and antibody response in relation to COVID-19
   severity. J Clin Invest.
- Weiskopf, D., Schmitz, K.S., Raadsen, M.P., Grifoni, A., Okba, N.M.A., Endeman, H., van den
- 38 Akker, J.P.C., Molenkamp, R., Koopmans, M.P.G., van Gorp, E.C.M., et al. (2020). Phenotype
- and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory
   distress syndrome. Sci Immunol 5.
- 41 Wu, D., and Yang, X.O. (2020). TH17 responses in cytokine storm of COVID-19: An emerging
- 42 target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect *53*, 368-370.
- 43 Xie, S., Huang, J., Qiao, Q., Zang, W., Hong, S., Tan, H., Dong, C., Yang, Z., and Ni, L. (2018).
- 44 Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma
- 45 tumors. Cancer Immunol Immunother *67*, 1685-1694.

1 2 3 4 5 6 7 8	<ul> <li>Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8, 420-422.</li> <li>Zheng, H.Y., Zhang, M., Yang, C.X., Zhang, N., Wang, X.C., Yang, X.P., Dong, X.Q., and Zheng, Y.T. (2020). Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol 17, 541-543.</li> </ul>
9	
10	
11	
12	
13	
14	
15	
16	
17	
18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	

#### 1 STAR METHODS

### 2 KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER					
Antibodies							
Anti-CD45 (clone H130)	BioLegend	Cat# 304028					
Anti-CD3 (clone OKT3)	BioLegend	Cat# 317334					
Anti-CD8 (clone SK1)	BD Biosciences	Cat# 557834					
Anti-CD56 (clone HCD56)	BioLegend	Cat# 318304					
Chemicals, Peptides, and Recombinant Proteins							
Fixable viability dye eFluor660	eBioscience	Cat# 65-0864					
FcR blocking reagent	Meltenyi Biotec,	Cat# 130-059-901					
Ficoll-Hypaque gradient	GE Healthcare	Cat# 17144002					
Goat anti-human IgM/HRP	Biosynthesis	Cat#bs-0345G-					
Goat anti-human IgG(biotin)	Sino Biological	Cat# SSA009					
HRP Mcab mouse anti-human IgG1	Cellwaylab	Cat# C030248					
HRP Mcab mouse anti-human IgG2	Cellwaylab	Cat# C030245					
HRP Mcab mouse anti-human IgG3	Cellwaylab	Cat# C030246					
TMB substrate	Invitrogen	Cat# 00-4201-56					
Mouse anti-His monoclonal antibody	Proteintech	Cat# HRP-66005					
Recombinant His-tagged NP of SARS-CoV-2	In-house	N/A					
Recombinant His-tagged S-RBD of SARS-	In-house	N/A					
Critical Commerc	ial Assays						
Fixation/Permeabilization Solution Kit	BD Biosciences	Cat# 554714					
Human IFN-γELISpot <sup>pro</sup> kit	MABTECH Cat# 3420-2A						
Biological Sa	mples						
Human AB serum	GemCell	Cat# 100-512					
Sera from HD#1-9	In-house	N/A					
Blood samples from HD#10-14	Institute of N/A Microbiology and						
convalescent samples from COVID-19 patients	ChuiYangLiu Hospital	N/A					
Blood samples from severe COVID-19 patients	Ditan Hospital N/A						
Deposited Data							
N/A	N/A N/A						
Experimental Models: Organisms/Strains							
HuH-7 CellsNie et al., 2020N/A							
Software and Algorithms							

FlowJo software v10.7	FlowJo LLC	https://www.flowjo .com/;RRID:SC R_008520

1

#### 2 **RESOURCE AVAILABILITY**

#### 3 Lead Contact

- 4 Further information and requests for resources and reagents should be directed to
- 5 and will be fulfilled by the lead contact, Chen Dong (chendong@tsinghua.edu.cn)

#### 6 *Materials Availability*

- 7 The plasmids (pET28-N-6XHis and pEF1a-S-RBD-6His) generated in this study will
- 8 be made available on request from the Lead Contact without restriction.

#### 9 Data and Code Availability

10 The study did not generate any unique dataset or code.

11

#### 12 EXPERIMENTAL MODEL AND SUBJECT DETAILS

#### 13 COVID-19 patient blood samples

14 The blood samples of severe COVID-19 patients defined as severe lower 15 respiratory tract infection or pneumonia with fever plus any one of the following: 16 tachypnea, respiratory distress, or oxygen saturation less than 93% on room air 17 according to the guidelines released by the national Health Commission of China 18 were obtained from Ditan hospital in Beijing. All procedures followed were in 19 accordance with the ethical standards of the responsible committee on human 20 experimentation (the institutional review board at Tsinghua University and at Ditan 21 hospital) and with the Helsinki Declaration of 1975, as revised in 2000. All studies 22 were approved by the Medical Ethical Committee at Tsinghua University. Informed 23 consent was obtained from all subjects for being included in the study. All patient

- 1 data were anonymized before study inclusion. See Table 1 for full patient information,
- 2 including age, sex, and health status.
- 3
- 4 Cell Lines
- 5 HuH-7 cells originally taken from a liver tumor in a Japanese male were cultured in
- 6 DMEM supplemented with 10% FBS. Cells were grown at 37 °C in a 5% CO2 setting.
- 7

#### 8 METHOD DETAILS

#### 9 Expression and Purification of recombinant proteins

10 The recombinant His-tagged NP of SARS-CoV-2 was expressed in E. coli by a T7

11 expression system, with 1 mM IPTG induction at 37 °C for 4 h. The recombinant His-

tagged S-RBD (amino acids 319-541) was expressed by a mammalian system in
293F cells. Purified proteins were identified by SDS-PAGE gels and stained with
Coomassie blue.

15

#### 16 **Isolation of PBMC**

17 PBMCs were isolated from anti-coagulant blood using Ficoll-Hypague gradients (GE Healthcare Life Sciences, Philadelphia, PA) as previously described (Xie et al., 2018) 18 19 under the biosafety level 3 facility in AMMS. To isolate PBMCs, blood diluted with 20 PBS, was gently layered over an equal volume of Ficoll in a Falcon tube and 21 centrifuged for 30-40 minutes at 400-500 g without brake. Four layers formed, each 22 containing different cell types. The second layer contained PBMCs. These cells 23 could be gently removed using a Pasteur pipette and added to warm medium or PBS 24 to wash off any remaining platelets. The pelleted cells were then counted and the

percentage viability was estimated using Trypan blue staining. Cells were then
 cryopreserved for future study.

3

#### 4 Anti-SARS-CoV-2 IgG/IgM ELISA

5 For IgM/IgG testing, 96-well ELISA plates were coated overnight with recombinant NP and S-RBD (100 ng/well). The sera from COVID-19 patients were incubated for 1 6 7 h at 37°C. An anti-Human IgG-biotin conjugated monoclonal antibody (Cat. SSA009, 8 Sino Biological Inc., Wayne, PA) and streptavidin-HRP were used at a dilution of 1: 9 5000 and 1:250, respectively, and anti-human IgM-HRP conjugated monoclonal 10 antibody (Cat. bs-0345G-HRP, Biosynthesis Biotechnology Inc. Beijing, China) was 11 used. The OD value at 450 nm was calculated. The area under the curve (AUC) was 12 calculated by Prism 8 (Graphpad). As a second analytical approach (Grifoni et al., 13 2020), the serum from one convalescent mild COVID-19 patient was used as a 14 positive control standard. In order to quantify the amount of anti-NP/S-RBD IgG or 15 anti-NP/S-RBD IgM present in each specimen, the positive control standard was run 16 on each plate to calculate antibody titers (relative units) for all samples using non-17 linear regression interpolations.

18

#### 19 Anti-SARS-CoV-2 IgG1/IgG3 ELISA

For IgG1/IgG2/IgG3 test, 96 well ELISA plates were coated (80 ng/well) overnight with recombinant NP and S-RBD. Plates were washed and the sera from COVID-19 patients were incubated for 1 h at 37°C. After washing, an anti-Human IgG1-HRP conjugated monoclonal antibody (Cat. C030248, BaiaoTong Experiment Center, LY), and an anti-human IgG3-HRP conjugated monoclonal antibody (Cat.C030246, BaiaoTong Experiment Center, LY), all validated by the company for their specificity,

were used at a dilution of 1:4000 for 1 h at RT. After washing, TMB substrate
 solution was added. The OD value at 450 nm was calculated. The area under the
 curve (AUC) was calculated by Prism 8 (Graphpad).

4

#### 5 Neutralizing antibody assay

6 Pseudovirus expressing the SARS-CoV-2 S protein was produced. pNL43Luci and 7 GP-pCAGGS were co-transfected into 293T cells. 48 hours later, SARS-CoV-2 8 pseudovirus-containing supernatants were mixed with at least 6 serially diluted 9 serum samples from the COVID-19 patients at 37°C for 1 hour. Then the mixtures 10 were transferred to 96-well plates containing monolayers of Huh-7 cells (Nie et al., 11 2020). 3 hours later, the medium was replaced. After incubation for 48 h, the cells 12 were washed, harvested in lysis buffer and analyzed for luciferase activity by the 13 addition of luciferase substrate. Inhibition rate = [1-(the sample group- the cell control 14 group) / (the virus control group- the cell control group)] x 100%. The neutralizing 15 antibody titer (NAT50) were calculated by performing S-fit analysis via Graphpad 16 Prism 7 software.

17

#### 18 Interferon Gamma (IFNγ) ELISpot

IFN-γ-secreting T cells were detected by Human IFNγ ELISpot<sup>pro</sup> kits (MABTECH AB,
Sweden) according to the manufacture protocol. Fresh PBMCs were plated in
duplicate at 150k per well and then incubated 48h with 1uM of recombinant proteins.
Spots were then counted using an AID ELIspot Reader System (iSpot, AID GmbH).
The number of spots was converted into the number of spots per million cells and
the mean of duplicate wells plotted.

#### **FACS** staining 1

2	PBMCs were washed with PBS plus 2% FBS (Gibco, Grand Island, NY), and then Fc
3	blocking reagent (Meltenyi Biotec, Inc., Auburn, CA) was added followed by a wash
4	with PBS plus 2% FBS. Cells were then incubated for 30 min on ice with anti-CD3
5	(OKT3) (BioLegend), anti-CD8 (SK1) (BD), anti-CD56 (HCD56) (BioLegend) and
6	live/dead fixable aqua dye (eF660, eBioscience), washed twice with PBS plus 2%
7	FBS and then stored at 4 $^\circ\text{C}$ until acquired by FACS Verse (BD Biosciences, San
8	Jose, CA). Data were analyzed using FlowJo software (Version 10.0.8, Tree Star
9	Inc., Ashland, Or).
10	
11	QUANTIFICATION AND STATISTICAL ANALYSIS
12	Prism 8 software is used for statistical analysis. Student's t test was performed for
13	two-group analysis. Pearson's correlation coefficients were calculated. P values less
14	than 0.05 were considered to be statistically significant.
15	
16	
17	
18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33	

Table 1 Clinical and pathological characteristics of the severe COVID-19 patients

Pt#	Sex	Age	Fever	Fatigue	ARDS	Lymphocyte Count	Days in hospital	Sampling day post onset	BT NA test	Discharge CT scan	Discharge NA test
#1	F	69	yes	no	yes	0.65X10 <sup>9</sup> /L	43	13	Ρ	improvement	Ν
#2	М	55	yes	no	yes	1.24X10 <sup>9</sup> /L	27	18	Ρ	improvement	Ν
#3	М	37	yes	no	yes	0.53X10 <sup>9</sup> /L	47	19	Ρ	improvement	Ν
#4	М	52	yes	no	yes	0.94X10 <sup>9</sup> /L	39	8	P	improvement	Ν
#5	F	58	yes	no	yes	0.78X10 <sup>9</sup> /L	50	12	Ρ	improvement	Ν
#6	М	40	yes	no	yes	1.13X10 <sup>9</sup> /L	51	11	Ρ	improvement	Ν
#7	F	70	yes	no	yes	0.75X109/L	36	11	Р	improvement	Ν
#8	F	66	yes	Yes	yes	0.69X10 <sup>9</sup> /L	43	2	Ρ	improvement	Ν
#9	М	66	yes	No	yes	0.92X10 <sup>9</sup> /L	82	4	Ρ	NA	NA
#10	F	62	yes	yes	yes	0.26X10 <sup>9</sup> /L	43	16	P	improvement	N

Notes: pt, patient; F, female; M, male; ARDS, acute respiratory distress syndrome; P, positive; N, 

negative; BT, before treatment; NA, nucleic acid; NA, non-available. 



В HD#10 Pt#3 1500 120<sub>-</sub> Pt#4 HD#11 Pt#5 HD#12 90. 1000  $NAT_{50}$  (log<sub>10</sub>) NAT50 Pt#6 HD#13 Pt#7 HD#14 60. 500 Pt#8 Pt#1 Pt#9 30. × Pt#2 Pt#10 0 0 1.5 2.5 3.0 3.5 2.0 4.0 1.0 Log serum dilution 2500ns D convalescent severe 2000-<30 NAT50 30-500 1500-500-1000 1000 >1000 500 convalescent severe

А

С

medRxiv preprint doi: https://doi.org/10.1101/2020.08.10.20171371; this version posted August 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.







А

medRxiv preprint doi: https://doi.org/10.1101/2020.08.10.20171371; this version posted August 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.